. Author manuscript; available in PMC: 2021 Jul 4.

Published in final edited form as: Nat Genet. 2021 Jan 4;53(1):65–75. doi: 10.1038/s41588-020-00748-0

Table 1.

Baseline Characteristics of the Participants.

	Multiancestry GWAS Sample Population Group										Replication Sample Population Group

	Total		European		African		East Asian		Hispanic		European (UK Biobank)		African (AFR CA UG)
	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
No. of participants	107,247	127,006	85,554	91,972	10,368	10,986	8,611	18,809	2,714	5,239	6,852	193,117	1,586	1,047
No. with individual level data ^a	84,574	65,134	71,570	52,531	9,126	8,702	1,652	1,803	2,226	2,098	6,852	193,117	1,586	1,047
No. ≤ 55 years of age	8,959	13,562	7,099	11,471	1,628	1848	47	81	185	162	481	79,347	354	277
No. with aggressive disease ^b	26,374	-	21,917	-	2,934	-	753	-	770	-	-	-	-	-

These participants are also included in GRS and stratified analyses.

Aggressive disease defined as stage T3/T4, regional lymph node involvement (N1), metastatic disease (M1), a tumor with a Gleason Score ≥ 8, or a prostate-specific antigen (PSA) level ≥ 20 ng/mL, or, prostate cancer as the underlying cause of death.